Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its products include TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma; TLX250, which is in Phase II for the diagnosis and treatment of renal cancer; TLX250-CDx, which is in Phase III for the imaging of clear cell renal cell cancer; TLX591, which is in pre-Phase III for the treatment of metastatic castrate-resistant prostate cancer; and TLX591-CDx, which is in Phase III for the imaging of prostate cancer. The company has collaboration agreements with Radboud University, University of Nantes/ARRONAX, University of Melbourne Osaka University, Winship Cancer Institute of Emory University, Merck Healthcare KGaA, and Memorial Sloan Kettering, as well as the Institute for Radiation Sciences, Osaka University and the Department of Nuclear Medicine, and Tracer Kinetics at Osaka University Graduate School of Medicine. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.01 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
TELIX Pharmaceutical (ASX:TLX) Frequently Asked Questions
What is TELIX Pharmaceutical's stock symbol?
TELIX Pharmaceutical trades on the ASX under the ticker symbol "TLX."
Has TELIX Pharmaceutical been receiving favorable news coverage?
News stories about TLX stock have trended somewhat negative on Thursday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. TELIX Pharmaceutical earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for TELIX Pharmaceutical.
Who are some of TELIX Pharmaceutical's key competitors?
Some companies that are related to TELIX Pharmaceutical include Mesoblast (MSB), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Paradigm Biopharmaceuticals (PAR), CEL-SCI (CVM), Cel-Sci (CVM), Oxford BioMedica (OXB), Bellus Health (BLU), Starpharma (SPL), Pfenex (PFNX), Pfenex (PFNX), Biotest (BIO), Trillium Therapeutics (TRIL) and Silence Therapeutics (SLN).
What other stocks do shareholders of TELIX Pharmaceutical own?
Who are TELIX Pharmaceutical's key executives?
TELIX Pharmaceutical's management team includes the folowing people:
- Dr. Christian P. Behrenbruch B.E., M.B.A., BEng(Hons), MBA, DPhil(Oxon), J.D., Co-Founder, MD, CEO & Director (Age 44)
- Mr. Douglas Cubbin FCPA, GAICD, Chief Financial Officer
- Dr. Jyoti Arora BappSc(Hons), Ph.D., Director of Operations
- Dr. Andreas Kluge M.D., Ph.D., Chief Medical Officer & Exec. Director
- Mr. Gabriel Liberatore, Group Chief Operating Officer
What is TELIX Pharmaceutical's stock price today?
One share of TLX stock can currently be purchased for approximately A$1.61.
How big of a company is TELIX Pharmaceutical?
What is TELIX Pharmaceutical's official website?
MarketBeat Community Rating for TELIX Pharmaceutical (ASX TLX)
MarketBeat's community ratings are surveys of what our community members think about TELIX Pharmaceutical and other stocks. Vote "Outperform" if you believe TLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
